NEW YORK (TheStreet) -- The most expensive playoff game to see this week is the New Orleans Saints' game in Seattle against the Seahawks, with the cheapest ticket on TicketCity going for $134. TicketCity found that the average ticket price for Saturday's game is a whopping $360.
This weekend, the NFL divisional playoffs might be heating up, but are fans paying up to see them?
"There are a few key factors that are driving record demand for the Saints/Seahawks game. The Saints have earned the franchise's first-ever road post-season victory, ending the drought at 0-5. On the other side, the Seahawks have recorded double digit victories in consecutive seasons while their fans continue to break attendance and noise records. It's the perfect storm for driving one of the most expensive divisional game tickets we've seen in recent years," said TicketCity COO Zach Anderson.
This weekend's San Diego Chargers/Denver Broncos game also makes the list of most expensive playoff games in recent years. To see one of the biggest stars in the NFL, Peyton Manning, and the Broncos host the Chargers, the average ticket on TicketCity will cost you $321.
While ticket prices for the Chargers/Broncos matchup are very similar to last year's AFC div playoff game, according to TicketCity Communications Director Meredith Owen, different factors are driving demand this year compared to last. Owen says that Ray Lewis' retirement announcement leading into the post season was a major contributor in demand for the Ravens/Broncos 2013 playoff game, while this year's prices are being driven by the fact that the two historical rivals are facing off in the post-season for the first time ever.
But the most expensive playoff game in the last five years goes to the Saints and the 49ers when they played in San Francisco in 2012. After the Saints went undefeated at home and the 49ers had their first post-season appearance since 2001 -- the average ticket price went for $405... a ! far cry from $84 for the cheapest ticket on TicketCity to see the New England Patriots play the Indianapolis Colts this weekend.
Written by Brittany Umar in New York.
5 Best Diversified Bank Stocks To Own For 2015: Diana Shipping inc. (DSX)
Diana Shipping Inc. provides shipping transportation services. It transports dry bulk cargoes that include commodities, such as iron ore, coal, grain, and other materials along worldwide shipping routes. As of December 31, 2010, the company?s fleet consisted of 23 dry bulk carriers, including 14 Panamax, 1 Post-Panamax, and 8 Capesize dry bulk carriers with a combined carrying capacity of approximately 2.5 million deadweight tonnage. Its customers include national, regional, and international companies. The company was formerly known as Diana Shipping Investments Corp. and changed its name to Diana Shipping Inc. in February 2005. Diana Shipping Inc. was founded in 1999 and is based in Athens, Greece.
Advisors' Opinion:- [By Nickey Friedman]
China announced it is shooting for 7.5% GDP for 2014. At the sound of that target, DryShips (NASDAQ: DRYS ) and�Diana Shipping (NYSE: DSX ) are likely celebrating. China is the primary country these days responsible for rising market rates for dry shipping, but something in the announcement may warrant a bit of caution.
- [By Terri Stridsberg]
Not to be outdone, Diana Shipping (DSX) has trekked 67.5% higher so far this year, and sports a 52-week gain of more than 72% to wink at the $12.20 level. Even so, the equity saw a 28.2% rise in short interest during the second half of September, and a 35.1% surge during the past two reporting periods.
- [By Nickey Friedman]
Diana Shipping (NYSE: DSX ) is pure investment in dry shipping. The company transports dry bulk cargoes worldwide, including commodities such as iron ore, coal, grain, and other materials. Analysts have yet to respond to the rate increases, but no doubt more of them will be raising their 2014 EPS estimates shortly. Diana Shipping trades around 20% below book value now; back in its heyday, it traded north of $40 per share.
Best Cheapest Stocks To Own For 2014: Centrex Metals Ltd (CXM)
Centrex Metals Limited (Centrex) is an Australia-based company engaged in iron ore exploration on wholly owned tenements in conjunction with joint venture partners Wuhan Iron & Steel (Group) Co. (WISCO) and Baotou Iron & Steel (Group) Co. (Baotou). The Company�� principal projects include WISCO joint ventures (Eyre Iron: Centrex 40%, Port Spencer: Centrex 50%), Bungalow joint venture (Centrex 70%), Wilgerup (Centrex 100%) and Exploration (Centrex 100%). The Bungalow / Minbrie magnetite deposit is located 9 kilometers north of the coastal town of Cowell on the Eyre Peninsula and around 100 kilometers from the Port Spencer joint venture site. The Goulburn and Archer tenements cover an extensive area with a number of base metal, gold and iron deposits and occurrences. Advisors' Opinion:- [By James E. Brumley]
To say that Cardium Therapeutics Inc. (NYSEMKT:CXM) has been unimpressive this year - and last year for that matter - would be an understatement. Shares of CXM peaked at $11.90 in late 2011, and spend the next two years making their way back to the August (2013) low of $0.58. The stock has since wiggled its way back to the current price of $0.84, but the effort has largely been dismissed as volatility. Big mistake. When you take a step back and look at the bigger picture, you start to see Cardium Therapeutics shares are on the cusp of a monster-sized rebound.
- [By James E. Brumley]
Call it a hunch (because that's all it is), but I think Cardium Therapeutics Inc. (NYSEMKT:CXM) at least belongs on your watchlist, if not already in your portfolio. CXM shares have dropped a handful of key hints that say the bulls are just one good nudge away from catapulting this stock upward.
Best Cheapest Stocks To Own For 2014: Flexpoint Sensor Systems Inc (FLXT)
Flexpoint Sensor Systems, Inc.(Flexpoint), incorporated on June 11, 1992, is a development stage company. The Company is principally engaged in designing, engineering and manufacturing bend sensor technology and products using its patented Bend Sensor technology. Flexpoint manufactures, and has jointly developed, six products that are being sold and supplied to customers. Flexpoint owns nine patents, including patents on specific devices that use the Bend Sensor. The Company works with various Tier 1 (major) automotive suppliers on a variety of products that are in various stages of development and implementation.
Bend Sensor Technology
Flexpoint owns the patent rights to the Company's Bend Sensor technology through Sensitron, Inc. (Sensitron), a wholly owned subsidiary of the Company. The Bend Sensor is a potentiometer bend sensor product consisting of a coated substrate, such as plastic, that changes electrical conductivity as it is bent in a consistent manner. Electronic systems can connect to this sensor and measure in detail the amount of bending or movement that occurs in a predictable manner. A potentiometer functions through the means of metal contacts swiping or rubbing across a resistive element. Flexpoin�� Bend Sensor potentiometer is a single layer with no mechanical assembly that makes it more reliable and smaller, and lighter in weight.
Automotive Products
Flexpoint has developed comfort seat for automobiles utilizing its patented Bend Sensortechnology and is working with Tier 1 suppliers on development of the seat and various seat related controls. Through a joint development arrangement with a Tier1supplier Flexpoint developed and delivered prototypes of the seat. Automobile manufacture has partnered with a Tier 1 supplier and is in the final stages of evaluating Flexpoint�� patented horn switch to replace their existing technology. The automobile manufacturer is also evaluating the use of the Bend Sensor as a switch to open rear! doors of SUV's and as a seat belt reminder (SBR). While working with various Tier 1 automotive suppliers the Company has developed and tested a SBR sensor that alerts the occupant of an automobile to fasten his/her seatbelt.
Flexpoint is working with multiple manufacturers to replace existing devices in the marketplace with a system superior in performance. Four separate and independent automotive suppliers and OEMs tested the Bend Sensor device for use in pedestrian impact detection device. The tests proved that the Bend Sensor device was able to detect impact with a human leg and in the event of an accident and trigger the desired safety response. Flexpoint has also developed a crash sensor, which is a series of sensors mounted in strategic places on the side and door panels of an automobile to detect an impact, as well as the speed, direction and force of the impact. This allows an onboard computer to deploy side air bags where needed. Using the same concept as the Company's automotive seat belt reminder (SBR), this device monitors cinema theater's paying customers and identifies available seats. Flexpoint has supplied a theater management firm with several prototype sensors, which have undergone extensive testing for this application.
As of December 31, 2012, Flexpoint developed and produced 20 prototype medical beds that assist in the management of bed sores. Using the Bend Sensor technology and accompanying electronics the bed is able to determine the position of the person in the bed and how they are moved. The Company has developed a vibration sensor, a rupture disc/bursting disc utilizing the Bend Sensor as the detection/alarm element of a rupture disc device, an infant bed cover using its patented sensors that is used to monitor infants in the prevention of sudden infant death syndrome (SIDS), toys and video gaming devices, and sports applications.
Advisors' Opinion:- [By CRWE]
Today, FLXT has shed (-6.25%) down -0.0060 at $.0900 with 19,500 shares in play thus far (ref. google finance Delayed: 11:10AM EDT September 25, 2013).
Flexpoint Sensor Systems, Inc. previously reported they expect to complete both Phase Two and Phase Three of development of the colonoscope application during the remainder of 2013. The company will receive milestone cash payments for each stage of the development process.
Best Cheapest Stocks To Own For 2014: Exelixis Inc.(EXEL)
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer. It focuses on developing Cabozantinib, an inhibitor of tumor growth, metastasis, and angiogenesis that target MET, VEGFR2, and RET, which are key kinases involved in the development and progression of various cancers. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular cancer, and melanoma. In addition, Exelixis, Inc. involves in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, Genentech, Inc., Boehringer Ingelheim Gm bH, and GlaxoSmithKline and Daiichi Sankyo Company Limited. Its products under development through collaborations include XL475, XL281, XL139, and XL413 inhibitors; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147, XL765, and isoform-selective PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; sphingosine-1-phosphate type 1 receptor; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Selena Maranjian]
Finally, SAC Capital's biggest closed positions included Coach�and Dover. Other closed positions of interest include Exelixis (NASDAQ: EXEL ) and, also,�Tronox Ltd. (NYSE: TROX ) . Biotech company Exelixis recently reported non-blowout early sales of its thyroid cancer drug, Cometriq. Some are waiting to see if the drug gets approved to treat prostate cancer, too, and the company is looking at treating as many as nine different�conditions with it, such as bone tumors. On the other hand, Cometriq is expensive, and the company's debt has been growing, along with its share count.
- [By Garrett Cook]
Exelixis (NASDAQ: EXEL) shares shot up 4.96 percent to $3.49 after the company announced positive phase 3 data for coBRIM.
Shares of Kandi Technolgies Group (NASDAQ: KNDI) got a boost, shooting up 10.45 percent to $16.26 on report of a 238% rise in EV sales.
- [By Roberto Pedone]
Another under-$10 biotechnology player that's starting to trend within range of triggering a near-term breakout trade is Exelixis (EXEL), which develops small molecule therapies for the treatment of cancer in the U.S. This stock has been crushed by the bears so far in 2014, with shares down sharply by 41%.
If you look at the chart for Exelixis, you'll notice that EXEL has been trending sideways and consolidating for the last two months and change, with shares moving between $3.02 on the downside and $3.84 on the upside. Shares of EXEL are starting to spike higher today right off its 50-day moving average of $3.42 a share. That spike is quickly pushing shares of EXEL within range of triggering a near-term breakout trade above some key overhead resistance levels.
Market players should now look for long-biased trades in EXEL if it manages to break out above some near-term overhead resistance levels at $3.55 to $3.63 a share and then once it clears more resistance at $3.84 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 4.85 million shares. If that breakout kicks off soon, then EXEL will set up to re-test or possibly take out its next major overhead resistance level at its March gap-down-day high of $4.50 a share. Any high-volume move above $4.50 will then give EXEL a chance to re-fill some of its previous gap-down-day zone that started at $6.66 a share.
Traders can look to buy EXEL off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.18 to $3.02 a share. One can also buy EXEL off strength once it starts to move above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment